ERBB2 and breast carcinoma: Further, for the postmenopausal hormonal receptor-positive early breast cancer patients from the combined cohort derived from the combined TransATAC and ABCSG-8 trial, they observed HRs of 3.75 (95% CI: 2.19–6.41) for intermediate- vs. low-risk and 5.49 (95% CI: 2.92–10.35) for high- vs. low-risk groups in the HER2- node-negative patient subgroup with distant recurrence between 5 and 10 years as the survival endpoint [10].